Innovate UK has opened two SME funding competitions worth a combined £11.1m for frontier artificial intelligence and engineering biology projects with credible routes towards commercial scale.
The programmes use different funding structures and target different stages of technology development, but both seek to help smaller UK companies turn technically ambitious work into products, services or platforms capable of attracting further investment.
Under Frontier AI: SME Champions, UK-registered micro, small and medium-sized businesses can apply for a share of up to £3.1m to run feasibility studies into advanced artificial intelligence and machine-learning technologies.
The competition is aimed at genuinely novel technology rather than routine use of existing AI products. Projects need to demonstrate ambitious technical development and a clear route to defensible scale-up, with applicants required to work alone rather than through a consortium.
Eligible projects must have total costs between £150,000 and £250,000 and last between one and three months. Depending on business size, grant funding can cover up to 70% of eligible costs. Applications close on 11 November.
The short project window makes the programme primarily a technical validation exercise. Companies are being offered public funding to establish whether difficult concepts can meet measurable performance objectives before substantially more capital is committed to development and commercial deployment.
A separate Engineering Biology Investor Partnerships competition offers up to £8m for UK SMEs developing engineering biology products and services closer to market. Projects must be carried out in the UK and applicants must intend to exploit their results domestically.
Private capital is built directly into that programme. A company must secure aligned investment from an approved lead investor worth at least twice the amount of grant funding, with the investment agreed on commercial terms separately from Innovate UK.
The grant itself can support up to 45% of eligible experimental-development costs for micro and small businesses and up to 35% for medium-sized companies. The associated private investment can finance wider company growth as well as expenditure that would not qualify for the grant.
Applications for the engineering biology programme close on 2 December. Companies assessed as eligible for grant support will then have until July 2027 to reach heads of terms with a lead investor, with projects required to begin by December 2027.
The two competitions reflect different financing problems within frontier technology. An early AI company may need a relatively contained feasibility project to prove that a novel method works before pursuing a larger funding round, while engineering biology frequently involves longer development cycles, specialist facilities and substantial capital before a product reaches market.
In the latter programme, requiring private investment alongside public funding gives Innovate UK an external commercial test as well as a technical assessment. Investors must be willing to commit at least twice the grant amount, placing considerably more private capital behind successful projects than the government contributes directly.
Both programmes also sit within a broader policy effort to keep more value from UK-developed technology within the domestic economy. Grant recipients must carry out relevant work in Britain and, in the engineering biology programme, explicitly intend to exploit the results from or in the UK.
Funding remains competitive rather than automatic, and Innovate UK can allocate less than the headline amount if applications do not meet the required standard. Companies that secure support will still face the larger challenge beyond the grant: converting promising technology into a business capable of attracting customers and follow-on capital without relying indefinitely on public funding.
You must be logged in to post a comment.